UNSPSC 51372317: Norpipanone

This classification denotes an analgesic agent with the molecular formula C23H29NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 127X8DJ74M, chemically known as 4,4-diphenyl-6-piperidino-3-hexanon but generally known as norpipanone, which bears US NIH Compound Identifier 22391. European Medicines Agency schedules Norpipanone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09378MIG. The term NORPIPANONE is an International Non-Proprietary Name.

UNSPSC 51372317 Norpipanone, a Commodity code, shows limited recent activity in state and local procurement. The single recent opportunity on record—Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026—addresses naloxone and drug deactivation systems rather than norpipanone itself. The mismatch between the code's nominal scope and the actual solicitation suggests the code does not reflect current state and local buying patterns for this chemical commodity. Seminole County's procurement was structured as a competitive bid for annual supply of 1,900 units of naloxone and 800 safe drug deactivation systems, with quarterly deliveries to the Seminole County Community Health Building. The contract included a two-year initial term with a one-year renewal option, fixed-fee pricing, standard compliance requirements (drug-free workplace, E-Verify), and insurance mandates (workers' compensation, commercial general liability, professional liability). Potential FEMA funding introduced federal compliance layers including Clean Air Act and Federal Water Pollution Control Act adherence.

The sourced opportunity provides insufficient geographic or issuing-body pattern to characterize market concentration. Seminole County represents a health and social services end-user pursuing pharmaceutical supply through local procurement channels. With only one tracked opportunity and a documented mismatch between code taxonomy and actual commodities being purchased, this code warrants monitoring rather than active pursuit at this time. Firms holding naloxone or pharmaceutical deactivation-system capabilities may find sporadic health department and emergency-services demand, but the UNSPSC coding does not reliably surface those opportunities.